TrialEuropean journal of clinical pharmacology2019

Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.

Hassan Seddik et al.PubMed ↗Publisher ↗

No numbers read from the abstract.